Search

Leslie Z Benet

from San Francisco, CA
Age ~87
Get Report
Also known as:
Leslie Dr Benet, Leslie A Benet, Lesle Benet, Leslie Bent
Phone and address:
601 Van Ness Ave, San Francisco, CA 94102
(415) 775-7954
Related to:
Reed M Benet, 62Carol A Benet, 85Jacqueline Benet, 60Benet Alexander, 32Adam T Sella, 52Jacqueline Benet, 43Jonas J BenetUri Sella, 59Gillian B Sella, 59
Connected to:
Guillermo Benet, 50Paul Benet, 42Marilyn M Benetatos, 69Cynthia S Beneteau, 48David D Beneteau, 45Richard K Beneteau, 33Karen Benetello, 51Marla B Benett, 73Leandro V Benetti, 32Marco A Benetti, 63

Leslie Benet Phones & Addresses

  • 601 Van Ness Ave, San Francisco, CA 94102 (415) 775-7954
  • 601 Van Ness Ave APT 56, San Francisco, CA 94102 (415) 775-7954
  • Cincinnati, OH
  • Stinson Beach, CA
  • Mill Valley, CA
  • 53 Beach Rd, Belvedere Tiburon, CA 94920 (415) 435-3550 (415) 435-6983
  • Belvedere, CA
  • South San Francisco, CA
  • Sanger, CA

Work

Company: Ucsf Position: Professor

Education

School / High School: University of California, San Francisco 1963 to 1965

Industries

Pharmaceuticals

Resumes

Resumes

Leslie Benet Photo 1

Professor Schools Of Pharmacy And Medicine

View page
Location:
San Francisco, CA
Industry:
Pharmaceuticals
Work:
UCSF
Professor
Education:
University of California, San Francisco 1963 - 1965

Business Records

Name / Title
Company / Classification
Phones & Addresses
Leslie Z Benet
Director
Impax Laboratories
Pharmaceuticals · Mfg of Pharmaceutical Preparations · Mfg Pharmaceutical Preparations · Pharmaceutical Preparations · Pharmaceutical Preparation Mfg · Drug Millers · Pharmaceutical Preparation Manufacturing
30831 Huntwood Ave, Hayward, CA 94544
2390 E Camelback Rd, Phoenix, AZ 85016
Director 30831 Huntwood Ave, Hayward, CA 94544
(510) 476-2000, (510) 471-3600, (510) 471-3200, (215) 289-2220
Leslie Z. Benet
President
INTERNATIONAL PHARMACEUTICAL FEDERATION, U.S.A
533 Parnassus Ave ROOM U68, San Francisco, CA 94143
Leslie Z. Benet
President
AVMAX, INC
385 Oyster Pt Blvd STE 9A, South San Francisco, CA 94080
Leslie Z. Benet
President
OXON MEDICA, INC
385 Oyster Pt Blvd SUITE 9A, South San Francisco, CA 94080
Leslie Z. Benet
Benet Associates, L.P
53 Bch Rd, Tiburon, CA 94920
(415) 435-3550

Publications

Isbn (Books And Publications)

Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development

View page
Author

Leslie Z. Benet

ISBN #

0306443562

Clinical Applications of Mifepristone: Assessing the Science and Recommending a Research Agenda

View page
Author

Leslie Z. Benet

ISBN #

0309049490

Giving Full Measure to Countermeasures: Addressing Problems in the DOD Program to Develop Medical Countermeasures Against Biological Warfare Agents

View page
Author

Leslie Z. Benet

ISBN #

0309091535

The Effect of Disease States on Drug Pharmacokinetics: A Symposium, 123rd Annual Meeting, American Pharmaceutical Association, New Orleans, Louisiana, April, 1976

View page
Author

Leslie Z. Benet

ISBN #

0917330110

Pharmacokinetic Basis for Drug Treatment

View page
Author

Leslie Z. Benet

ISBN #

0890048746

Us Patents

Use Of Ugt Inhibitors To Increase Bioavailability

View page
US Patent:
20030215462, Nov 20, 2003
Filed:
Dec 20, 2002
Appl. No.:
10/327367
Inventors:
Vincent Wacher - Carlsbad CA, US
Leslie Benet - Belvedere CA, US
International Classification:
A61K035/78
A61K031/7072
A61K031/7048
A61K031/485
A61K031/4745
A61K031/7024
A61K031/16
US Classification:
424/195180, 424/777000, 424/776000, 424/778000, 424/747000, 514/027000, 514/023000, 514/282000, 514/182000, 514/049000, 514/283000, 514/532000, 514/546000, 514/625000
Abstract:
Methods for increasing the bioavailability of certain orally administered pharmaceutical compounds by the coadministration of inhibitors of UDP-glucuronosyltransferase (UGT) are disclosed. Particular combinations of UGT inhibitors and pharmaceutical compound are described.

Treatment Of Pharmacological-Induced Hypochlorhydria

View page
US Patent:
20130096116, Apr 18, 2013
Filed:
Oct 12, 2012
Appl. No.:
13/650274
Inventors:
Brian James Dean - Half Moon Bay CA, US
Mark Jason Dresser - San Francisco CA, US
Adam Frymoyer - San Carlos CA, US
Scott Naylor Holden - San Francisco CA, US
Jin Yan Jin - Foster City CA, US
Joseph Alan Ware - Los Altos CA, US
Leslie Z. Benet - San Francisco CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 31/5377
A61P 35/00
US Classification:
5142342
Abstract:
Changes in gastric pH due to oral co-administration of acid-reducing agents, such as proton pump inhibitors, and oncology drugs can have a marked impact on the absorption and oral bioavailability of the oncology drug if the pH decreases the maximal absorbable dose. Moreover, there is a potential for specific drug-drug interactions between some of the acid-reducing agents and these drugs. Methods are described for treating patients on gastric acid-reducing therapy with orally-administered PI3K inhibitor compound GDC-0941. Treatment with a re-acidification compound during treatment with GDC-0941 improves bioavailability of GDC-0941.

Propyl Gallate To Increase Bioavailability Of Orally Administered Pharmaceutical Compounds

View page
US Patent:
59625228, Oct 5, 1999
Filed:
Sep 5, 1997
Appl. No.:
8/926309
Inventors:
Vincent J. Wacher - San Francisco CA
Leslie Z. Benet - Belvedere CA
Assignee:
AvMax, Inc. - Berkeley CA
International Classification:
A61K 31235
US Classification:
514544
Abstract:
A method for increasing bioavailability of an orally administered pharmaceutical compound comprises orally administering the pharmaceutical compound to a mammal in need of treatment with the compound concurrently with propyl gallate. Improved formulations of pharmaceutical compounds include propyl gallate to enhance the bioavailability of the active ingredient of the pharmaceutical compound.

Use Of Essential Oils To Increase Bioavailability Of Oral Pharmaceutical Compounds

View page
US Patent:
57169284, Feb 10, 1998
Filed:
Jun 7, 1995
Appl. No.:
8/478207
Inventors:
Leslie Z. Benet - Belvedere CA
Vincent J. Wacher - San Francisco CA
Reed M. Benet - Belvedere CA
Assignee:
AvMax, Inc. - Berkeley CA
International Classification:
A61K 3112
US Classification:
514 11
Abstract:
A method for increasing bioavailability and reducing inter- and intra-individual variability of an orally administered hydrophobic pharmaceutical compound, which comprises orally administering the pharmaceutical compound to a mammal in need of treatment with the compound concurrently with an essential oil or essential oil component in an amount sufficient to provide bioavailability of the compound in the presence of the essential oil or essential oil component greater than bioavailability of the compound in the absence of the essential oil or essential oil component, wherein the essential oil or essential oil component has an activity of at least 10% inhibition at a concentration of 0. 01 wt. % or less in an assay that measures conversion of cyclosporine to hydroxylated products using an assay system containing 250/. mu. g rat liver microsomes, 1. mu.

Use Of Benzoin Gum To Inhibit P-Glycoprotein-Mediated Resistance Of Pharmaceutical Compounds

View page
US Patent:
59165669, Jun 29, 1999
Filed:
Feb 11, 1998
Appl. No.:
8/973593
Inventors:
Leslie Z. Benet - Belvedere CA
Vincent J. Wacher - San Francisco CA
Reed M. Benet - Belvedere CA
Assignee:
AvMax, Inc. - Berkeley CA
International Classification:
A61K 3578
A61K 31335
US Classification:
4241951
Abstract:
A method for increasing bioavailabilty of an orally administered hydrophobic pharmaceutical compound, which comprises orally administering the pharmaceutical compound to a mammal in need of treatment with the compound concurrently with an essential oil or essential oil component in an amount sufficient to provide bioavailability of the compound in the presence of the essential oil or essential oil component greater than bioavailability of the compound in the absence of the essential oil or essential oil component, wherein the essential oil or essential oil component has an activity of at least 10% inhibition at a concentration 0. 01 wt. % or less in an assay that measures reduced conversion of cyclosporine to hydroxylated products using an assay system containing 250. mu. g rat liver microsomes, 1. mu. M cyclosporine, and 1. mu.

Use Of Essential Oils To Increase Bioavailability Of Orally Administered Pharmaceutical Compounds

View page
US Patent:
61212342, Sep 19, 2000
Filed:
Feb 6, 1998
Appl. No.:
9/019936
Inventors:
Leslie Z. Benet - Belvedere CA
Vincent J. Wacher - San Francisco CA
Reed M. Benet - Belvedere CA
Assignee:
AvMax, Inc. - Berkeley CA
International Classification:
A61K 3112
US Classification:
514 11
Abstract:
A method for increasing bioavailability and reducing inter- and intra-individual variability of an orally administered hydrophobic pharmaceutical compound, which comprises orally coadministering the pharmaceutical compound to a mammal in need of treatment with the compound with an essential oil or essential oil component in an amount sufficient to provide bioavailability of the compound in the presence of the essential oil or essential oil component greater than bioavailability of the compound in the absence of the essential oil or essential oil component, wherein the essential oil or essential oil component has an activity of at least 10% inhibition at a concentration of 0. 01 wt. % or less in an assay that measures conversion of cyclosporine to hydroxylated products using an assay system containing 250. mu. g rat liver microsomes, 1. mu.

Use Of Gallic Acid Esters To Increase Bioavailability Of Orally Administered Pharmaceutical Compounds

View page
US Patent:
61806668, Jan 30, 2001
Filed:
Mar 5, 1999
Appl. No.:
9/264215
Inventors:
Vincent J. Wacher - San Francisco CA
Leslie Z. Benet - Belvedere CA
Assignee:
AnMax, Inc. - So. San Francisco CA
International Classification:
A61K 31235
A61K 31353
US Classification:
514544
Abstract:
A method is disclosed for increasing bioavailability of an orally administered pharmaceutical compound comprising orally coadministering the pharmaceutical compound to a mammal in need of treatment with the compound and a gallic acid ester. Preferred gallic acid esters of the invention include octyl gallate, propyl gallate, lauryl gallate, and methyl gallate. Improved formulations of pharmaceutical compounds include the gallic acid ester to enhance the bioavailability of the active ingredient of the pharmaceutical compound.

Use Of Essential Oils To Increase Bioavailability Of Oral Pharmaceutical Compounds

View page
US Patent:
56653867, Sep 9, 1997
Filed:
Jun 7, 1995
Appl. No.:
8/486186
Inventors:
Leslie Z. Benet - Belvedere CA
Vincent J. Wacher - San Francisco CA
Reed M. Benet - Belvedere CA
Assignee:
AvMax, Inc. - Berkeley CA
International Classification:
A61K 948
US Classification:
424451
Abstract:
A method for increasing bioavailability and reducing inter- and intra-individual variability of an orally administered hydrophobic pharmaceutical compound, which comprises orally administering the pharmaceutical compound to a mammal in need of treatment with the compound concurrently with an essential oil or essential oil component in an amount sufficient to provide bioavailability of the compound in the presence of the essential oil or essential oil component greater than bioavailability of the compound in the absence of the essential oil or essential oil component, wherein the essential oil or essential oil component has an activity of at least 10% inhibition at a concentration of 0. 01 wt. % or less in an assay that measures conversion of cyclosporine to hydroxylated products using an assay system containing 250. mu. g rat liver microsomes, 1. mu.

Wikipedia References

Leslie Benet Photo 2

Leslie Z. Benet

Control profile
Leslie Z Benet from San Francisco, CA, age ~87 Get Report